Xenon Pharmaceuticals (XENE) EBIT (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly EBIT of -$112.3 million for Q1 2026, down 54.43% year-over-year from -$246.5 million in Q1 2025, and down 2.33% quarter-over-quarter from -$109.8 million in Q4 2025.
Xenon Pharmaceuticals (XENE) EBIT (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported EBIT for 14 consecutive years, with -$112.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 54.43% year-over-year to -$112.3 million; the TTM figure through Mar 2026 stood at -$412.7 million (down 40.84% YoY), while the FY2025 annual figure was -$373.1 million, down 33.57% from the prior year.
- EBIT declined to -$112.3 million in Q1 2026 per XENE's latest filing, from -$109.8 million in the prior quarter.
- Across five years, EBIT topped out at -$17.4 million in Q1 2022 and bottomed at -$112.3 million in Q1 2026.
- Historically, EBIT has averaged -$65.2 million across 5 years, with a median of -$59.0 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT declined 8.16% — and 2023, when it slumped 182.41%.
- Xenon Pharmaceuticals' EBIT stood at -$43.3 million in 2022, then decreased by 23.92% to -$53.7 million in 2023, then tumbled by 44.29% to -$77.5 million in 2024, then tumbled by 41.68% to -$109.8 million in 2025, then declined by 2.33% to -$112.3 million in 2026.
- Business Quant data shows XENE's EBIT at -$112.3 million in Q1 2026, -$109.8 million in Q4 2025, and -$96.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -123.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -123.16 Mn |
| Mar 31, 2026 | -112.33 Mn |
| Dec 31, 2025 | -109.77 Mn |
| Sep 30, 2025 | -96.34 Mn |
| Jun 30, 2025 | -94.23 Mn |
| Mar 31, 2025 | -72.74 Mn |
| Dec 31, 2024 | -77.48 Mn |
| Sep 30, 2024 | -73.68 Mn |
| Jun 30, 2024 | -69.10 Mn |
| Mar 31, 2024 | -59.04 Mn |
| Dec 31, 2023 | -53.70 Mn |
| Sep 30, 2023 | -55.68 Mn |
| Jun 30, 2023 | -55.62 Mn |
| Mar 31, 2023 | -49.05 Mn |
| Dec 31, 2022 | -43.33 Mn |
| Sep 30, 2022 | -38.13 Mn |
| Jun 30, 2022 | -30.32 Mn |
| Mar 31, 2022 | -17.37 Mn |
| Dec 31, 2021 | -24.84 Mn |
| Sep 30, 2021 | -15.60 Mn |